Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Those with margin accounts automatically loan out their shares. However, with IRAs, they'll have to solicit and get permission from account holders.
He is with me, Karin. Thanks!
With a small grant, IND, one Phase II, and peer-review, we are looking at $2ish with 600mc to 700m mc valuation.
Imagine if NIH decides to grant $60m to 80mil? That's $1.3b or
$4ish?
Then raise another $100mil through PPF, expand clinical trial, pushes our valuation to about $2.3b, and get uploaded to NASDAQ and have at least four cv19 stages all in phase II.
Buy and hold. Accumulate. Investing in Bril drug as the n flagship is a risk-free investment with the company trading below $3 to $5b in the next 9 to 12 months. Jmo.
The short-term catalyst not inclusive of the projected $2.3b asks is a partnership and additional funding from B's OM initiation of Phase III.
Go big, buy, accumulate, and hold to on to your shares!
My summary of this company...it's a risk-free investment while their market cap is still under $5B dollars. Brilacidin will deliver!
Whether you believe it or not, that's your ownership. Our next trajectory pt is $2! 700mil mc. Easy-peasy, peaches!
The shorts' bugle boy?
Fair value at 48 to 82c to account for peer-review release. Global recognition of Bril, social media, news, and etc. Their valuation is still very cheap.
Here's why...
A small grant will allow us to initiate a Phase II trial for moderate and/ or mild patients. IND first and possibly EIND is not out of the question. Those milestones will push our valuation to up to $600mil to $700mil market valuation. Huge shorts covering at over $1 to fill above the $1.84 gap and push as to $2.
Can you imagine if the total grants exceed over $60mil or $80mil? This will push IPIX's valuation to at least $1.2b to extend other clinical trials and cover all cv19 sequelae.
The second wave of cv19 is coming that could result in trillions of global business losses. Vaccines are unlikely to be ready until next spring, IMO.
Great buying opportunity to buy, accumulate,e, and hold to achieve the next $2 price target.
Lastly, BRIL WILL BE A GUARANTEED SUCCESS AS THERAPEUTIC DRUG FOR CV19! The only question is, what are you going to do now with that information at this price before grant funding for Phase II is announced??
Know and understand why you buy and hold IPIX at this cheap price level!
GLTAL
GBA
FIDELITY AND SCHWAB are two...
JFM's moniker is the Punisher! LOL.
Agreed. I usually blocked them. Let only a few of address them head on (they know who they are), while the rest give out current news, pertinent and relevant information, and up to date news.
Keep the line moving.
#BrilacidinistheCovid19cure! Still was then and still is now. Peeps just didn't know about it back then in March.
Others refused to believe, or simply didn't know what they have in Bril.
Then you have the nematodes or "criminals" who didn't understand why and what they were betting against BRIL AND TIH!
600mil valuation is up with grant and one phase II moderate? Cv19 target?
Imagine if we get, say, $120mil total grants. Valuation jumps to $1.5b+ while all still in phase II trials and uplisting is next on NASDAQ
WHEN results of Phase II trials come out? No reason why our mc should not be at $3.5b with three to five cv19 pipelines
If pharma wants in for 20% stake (700m), negotiate with $10b arbitrary valuation to push to about $15b mc and extend all the cv19 to phase III, including AKI, too.
Really leverage BRIL 's first and foremost since clinical applications could push revenues close 10b. In five years, we could be next Celgene (at 135b at one point with 9b revs). Jmo.
Good point. An announcement of the rejected offer raises the valuation. Such rejection and acceptance can also be influenced and scrutinized by a controlling interest. If the action taken by BoD was deemed as not in good faith of shareholders' interest, then a mutiny can also happen.
Peter, you seriously need to stop shooting down people as if you know everything. You don't! GrandWalei does have a point.
Knowledge sometimes comes from experience and is not necessarily equated with wisdom that is associated with age.
MRNA, AZN, JNJ + BARDA are three of five vaccines bypassing preclinical trials that at least I know of. MRNA has some suspicious phase I results and questionable safety and tolerability concerns. Both companies use the messenger RNA platform. Those same problems in phase I will show up in phase II. Good luck with those two. That leaves two left out five.
Merck and PFE...I don't follow.
Just my thoughts. Crank out all the phase II testing for all sequelae stages of CV19 PLUS AKI, defer any partnership until results come out. If the offer is bad, flex and raise PPF, then sell for $10b cash plus 10b in CVR- preferably with a company's share ($5b) and another milestone for $5b. $15b is not bad at all.
A grand total of $20b. If not become the next Celgene that actually generates $10b or more in revenues with mc over 125b. But man, that's going to require a ton of work and massive sales force to execute sales.
$10b is the Alamo. All cash.
Steeleyeye is correct and you are playing with semantics here and possibly tiptoeing a bit, with subpar theatrical acting on your part. He must be admiring your subtleties, KLMNOP. And you're just doing your job since you have a vested interest in the company. That's fair enough.
First of all, Brilacidin is not Purisol.
Not a textbook play? I'm sorry, but the two drugs are entirely different compounds, with different MoA, and zero correlation to what clinical patients they are trying to address. Let me opine, and you can feel free to REPEAT THIS AFTER ME and say,
Purisol is a sunk cost. It's neither here nor there. They are two independent events!
Everybody knows that, correct?
The fact is, Brilacidin is a clinical drug that's been at least proven as safe and effective beyond midstage clinical trials!
It's been tested in 507 patients and potentially a groundbreaking therapeutic and prophylaxis drug in combating the covid19. It has the potential to address all flu pandemics ( and it will again : ) ) and not to mention other inflammatory disease and/or head and neck cancer.
Bril worked in two of three different epithelial cells that are involved and affected by the SARS-CoV virus. And the last validation of lung results with its p-value? That is highly likely to translate into a successful outcome in human clinical trials whether you believe it's 80% chances of failing or a 100% probability of success like what I'd think it will do. But that just my opinion.
What the bulls or bears wish to believe is up to them. The results in two human epithelial cells were simply astonishing, I must say. Did you see it coming?
Bril drug will be repurposed for the Phase II trial and more likely across all stages of Cv19 patients with grants and/or Private placement funding. There's no doubt in my mind that Bril will succeed with endpoints set so low. What you believe or how to wish to profit on that information is up to you.
Best of luck to you if you are betting against this Brilacidin drug company. It's your money. I'd go bullish if you haven't already! Our next stop is a Phase II milestone and it's valuation. I sense a $600+ mil valuation backed up with at least one phase II in moderate CV19 trial patients plus a small grant funding is very attainable.
No, I wasn't referring to you just because I responded to you directly. My comment was directed to Peter and his well-rounded talent in science and business acumen without humility.
Well, at least that's what his ego is telling everyone here. LOL. I am simply amused by his " eldership " and autocratic entitlement on this board when I didn't agree with him. Talk about having a fragile ego on his part. LOL. Good times here on this board, brother!
LOL. This board exists to sharpen everyone's bandwidth here when it comes to investing and science knowledge. If someone tries to pull this seniority entitlement using their ego approach over knowledge and experience? Good luck on that. LOL. That's not how you learn and grow.
You can never underestimate the contributions from others here whether they have connections or not.
Maybe it's because business is not your cup of tea? If any type of business arrangement, startup or not, you have two options: exit (sell) or persevere. But you would not know that since neither science nor business (background) you possess or is your strength.
You always weigh those two options above no matter what and you maintain an open mind.
Kevetrin anyone? LOL.
Thanks. I believe in my dd and my assumptions had never been faulty with what Bril can do with SARsCov2. 110% conviction that it will work. And it did! It was a Eureka moment for me when I found out about Bril last March. if I was not open-minded about investing in OTC "penny stock ", I would have missed out a ton!
Pennies on the dollar and is now looking like pennies on the DOLLARS!
If Leo needs consultation, I have a CFA and a Ph.D. in Finance connection referrals to help him weigh his options. Although this is also my cup of tea.
We can control several million shares of Ipix so we'll continue to accumulate.
#TAGB
I'm starting to think that with Bril being the cure for SARsCoV2 and potentially all pandemics, our starting negotiating valuation with at least one Phase II should be at least 20b-- regardless of what the actual market cap dictates.
A $20b arbitrary valuation is a good starting negotiation ( and to work down if necessary) for Leo if any big pharma wants in. If they want a meaty partnership (outside of PFE' a 500m).
So let's say XYZ wants a partnership with 20% ownership, that's a 400mm buy-in, but only after we have fully leveraged the CV19 PIPELINES and at the beginning of Phase III. Oh, man! Bril being the flagship with cv19 pandemic was the perfect storm that many parasites didn't criminals didn't see coming!
I'm throwing my $10b tag price out the window, Leo.
It seems people are still shocked by how great the lung results came in. Well, a very few weren't and pretty much knew it will be guaranteed success! ;)
I believe our mc will have a massive run to 400m to 600m... with the grant and phase II trial being announced. It seems that MODERATE cv19 is the ideal target. But if we get a bigger grant enough to run both mild and moderate, watch out World! I'm pegging our valuation to be trading close to $1.2b. It seems the version of nasal spray for mild case will be ideal if the oral version takes longer to produce.
Leo can possibly seek convertible preferreds for $10m to $20m in order to fund or just seek out PPF alternative and initiate a third and/or fourth phase II trials as well for severe and/or mild Cv19 patients. And on top of getting uplisted to NASDAQ.
I also believe that compassionate care usage of Bril in critically patients should be a great choice as a feeler to test the water first, before jumping straight to critically patients. But I tell you what, this Bril drug should work and will have a significant impact in reduced mortality rate! Going straight to critically ill patients will be a huge feat. A min 20% to 25% reduction in mortality rate will be statistically significant. Bril + ventilator vs Remde + ventilator for placebo. Lol.
After phase II results come back, then Leo can strike a deal with PFE if it makes business sense. Can you imagine having two or four cv19 pipelines?? And what that would do to our valuation? That's an easy $3b without phase II RESULTS coming out yet.
Next up is 500mc with GRANT FUNDING AND JUST ONE PHASE II clinical trial. Bril is on the cusp of being a great unicorn drug that will address all the pandemics, and possibly the majority of the viruses and bacterial pathogens out there as well.
To any hedgies reading this board, it's time for you to go long on this company! My free advice. If you need other ideas out there with poor management and mediocre science, feel free to track me down. I'll throw you guys bones. But avoid SHORTING THIS but go long instead with this company and get yourself paid with real money.
Drop the bomb, Leo! Time for you and BRIL TO SHINE, brother!
DROp THE BOMB on these food stamps penny flipping SOBs and criminals, LEO!
THE perfect set up to talk about over the weekend and next week that will go with lung results is a phase II trial announcement tomorrow.
Drop the phase II trial tomorrow's target date, to add more meat and excitement over the weekend and next week. Tell the world that you have applied for grants too!
Now have fun introducing Bril to the world with lung results and phase II TRIAL, LEO.
TIME FOR YOU TO SHINE, BROTHER! Own it, LEO! OWN IT! NOW OR NEVER, LEO. ALL MY OPINION ONLY.
#TAGB
Time to announce a Phase II trial tomorrow, LEO?
Yes, it's called PRIVATE OFFERING TO HELP FUND PHASE III trials when the sp is at 500mil min or more. More if the grant fund is enough to fund all four stages of cv19.
And when that PRIVATE OFFERING HAPPENS, our MC jumps over $1.2B with the grant funding and one PHASE II in play.
Can you imagine BRIL CURING HIV/AIDS too? Weekly pill for three to six months?
Pricing for a grant funding plus Phase II should be about $500mil mc. Fill that gap shorts!
This stock will close to $1B mc, if we get a huge grant and funding of about 80mil total or more.
We can fund all the sequelae (4)of cv19 and have two pipelines. Then uplist to NASDAQ. LET'S SEE THEM PEACHES RAIN DOWN ON US.
Btw, CONGRATS, LEO! NOW it's time for us to build that cv19 pipeline and possibly for other pandemics.
Make em pay!
#TAGB
Possibilities have to be translational in the clinical pipelines. You can't have a valuation based on perceived of what if application scenarios that's not how M&A works. It has to be real and proven from existing assets. And assets = clinical pipelines. Take the emotions out and see that it is just another business decision.
Well, if they're granting us 80mil, which would be great and help the economy, they can tell Leo what to do. But if it's a meager 4m, 5mil? That's not enough spread on the table. The host will have to come up with a financing deal if he wants a book reading club turning into a real formal party. Btw, I enjoy formal parties. ??
Buy us out for $5b all cash, I'm good with that. If we get to phase III trials, that doubles! PeterManix may disagree with me on Kevetrin but that's okay. I know my science and #s. : )
It's now or never is what will define Bril. I have the utmost confidence in Bril in potentially becoming the best in class treatment and future SOC in all segments of CV19 patients. Mild to moderate is a bit too easy, Imo. Too ordinary.
Yes, that's what I told this board. The receptors uptake and binding of Bril in human lungs are much higher and faster than the kidney cell assay results. The results for the lung is guaranteed.
It seems the addressable population will be much greater in both moderate and severe patients in terms of addressing the healthcare burden, Imo.
Moderate + severe vs mild and moderate vs severe and critically ill patients.
Nope, you don't partner until after phase II OR III results are out. That's how you leverage your negotiation based on mc size and data results. We will just get bamboozled at this point.
Severe vs critically ill are two different criteria of cv19 (sequela) patients. They're not the same. Understand this.
He definitely needs a CMO advisor. At least severe since that's where ARDS, pneumonia, and SEPSIS that Bril can address.
So he's just gonna just sit and milk the phase II results using grant funding?
That's bad advice. You cannot maximize shareholders' wealth without taking risks for both severe and critically ill patients. The primary endpoints are now secondary. I'm sure our results with Bril in mortality rate will be better than REMDESIVIR (THRASH).
I can guarantee you that Bril is as good or even better than Leronlimmab. BUT NOW IS NOT THE TIME TO SECOND GUESS BRIL'S 3-IN-1 ACTION. SEIZE THE DAY! LET THE JUGGERNAUT DOES ITS THING IN CV19 PATIENTS!
Scalability trials.
TIME FOR LEO TO BE ACTIVE, GET A CMO and CDMO ready. LINE UP A PRIVATE FUNDING AFTER PHASE II for mild to moderate to follow it up with another phase II trial with severe and critically ill patients to push us over $1b valuation and get uplisted on NASDAQ. Can't wait and rely on the government to give us bigger funding. But who knows? Maybe a 8O mil funding from BARDA will solve the capability trials. EIND? With fast track label!
MY free advice. #TAGB will continue to accumulate. Would be nice if he responds to my email or other TAGB members
Pure luck! Now, we need Leo to strike while the iron is hot.
He needs to get the phase II trial going in humans for mild to moderate with grant funding. That just pushes our valuation over $250m to $300m, then RAISE PRIVATE PLACEMENT TO INITIATE PHASE II for severe and critically ill patients. GET UPLISTED ON NASDAQ. That raise will push us close to $1b. WE GET ADVANCE TO PHASE III, then we will be at $2b or more. Then he can sell the company for at least $5 cash. $10b( with cvr)
I meant to type KIDNEY! higher than kidney cell assay!
Just as I predicted binding to lung epithelial cells is much quicker in receptors at a higher rate than lungs!
Guaranteed success!
Get the phase II ready for mild to moderate using grant money! After that, get the PRIVATE PLACEMENT TO FUND FOR PHASE II Severe and Critically ill patients.
Our valuation could easily push close 1b then get UPLISTED, Leo!
I say have a little faith in Bril! Get the phase II ready using the grant for mild to moderate CV19 patients. This should raise our valuation substantially between 250m to $300m+. I personally would not wait for the government to fund or give us another grant to do another clinical trial. We got to strike while the iron is hot, Leo!
Then follow that up with a private placement funding to do fund another subset of PII that targets severe and critically ill patients. This round of funding could easily push our valuation close to $1b, Leo. The round of financing should be enough to expand the team and get us uplisted to NASDAQ.
I am hoping once we get the phase II grant and if we are looking at only mild to moderate patients for a clinical trial, Leo should look into a private placement quickly to expand the trial to severe and critically ill patients population.
Just in general, the government is so slow in providing fundings to small companies when it came to cv19 therapeutics; and it seems their capital resources are more focused on vaccines that are dominated by big pharma players and hardly very little to therapeutics and prophylaxis. We may get the funding, but it may take much longer than usual. I am sure Leo can gauge this easily.
Private placement funding (ppf)is the best way to jump-start our valuation! We can have two pipelines working together to boost our sp and get approvals that have been condensed in a matter of four to five months for phase III trials. WITH ppf, it will allow us to get uplisted back on NASDAQ as well!
I'm sure Leo has a strong business acumen to foresee this thing and strike while the iron is hot. Timing is of the essence here! There are competitors out there so so we competition!
Get it done, Leo!
#TAGB!